Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIC – Antimicrobial Stewardship for Ventilator-Associated Pneumonia in Intensive Care
2024-513327-16-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amoxicillin + clavulanate in ventilator-associated pneumonia (VAP) and bacterial pneumonia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite primary endpoint (mortality, treatment failure, or new VAP episode by day 28). Planned start Sep 2024; status: authorised.
02
Drugs
amoxicillin + clavulanate
03
Conditions
ventilator-associated pneumonia (VAP)bacterial pneumonia
Beyond the preview
Go deeper on 2024-513327-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513327-16-00.